1. |
From the Editor |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 2-2
&NA;,
Preview
|
PDF (803KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
2. |
High stroke rate leads to early termination of thrombolytic trials |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 3-4
Jo Barnes,
Preview
|
PDF (1539KB)
|
|
摘要:
A higher than expected incidence of haemorrhagic stroke led researchers to suspend 3 major trials designed to compare the effects of hirudin with heparin. All 3 trials were investigating the effects of these antithrombotics in patients with myocardial infarction who were receiving thrombolytic therapy. This turn of events has raised serious questions regarding the optimal dose of both antithrombotics, with some researchers questioning whether heparin should be used at all in patients receiving streptokinase. Data from the halted trials, and details of new regimens for 2 of the studies, were presented at the joint 12th World Congress of Cardiology and 16th Congress of the European Society of Cardiology [Berlin, Germany; September 1994].
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
3. |
Views in the news |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 4-4
&NA;,
Preview
|
PDF (787KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 5-6
&NA;,
Preview
|
PDF (1457KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 6-6
&NA;,
Preview
|
PDF (721KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
6. |
The economic punch of sparfloxacin |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 7-7
Lori Bonertz,
Preview
|
PDF (728KB)
|
|
摘要:
The cost of treating community-acquired pneumonia may be reduced once sparfloxacin [Zagam®; Rhône-Poulenc Rorer, Dainippon] is introduced into general practice. The lower costs associated with the use of this new agent were indicated in a cost-effectiveness study presented at the 4th European Respiratory Society Annual Congress [Nice, France; October 1994]. The French data is of particular interest, as France recently became the first country in which sparfloxacin was launched.
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
7. |
Greatest improvement in QOL with lowest dose breast cancer therapy |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 8-8
&NA;,
Preview
|
PDF (725KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 9-9
&NA;,
Preview
|
PDF (728KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
9. |
Factors determining the response to HIVAC-1e + VaxSyn |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 10-10
&NA;,
Preview
|
PDF (725KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|
10. |
Cholesterol caught by its own chemistry |
|
Inpharma Weekly,
Volume &NA;,
Issue 961,
1994,
Page 11-11
&NA;,
Preview
|
PDF (711KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1994
数据来源: ADIS
|